|
|
|
|
||
Nice try at spin, Cptspr, but it comes up woefully shallow.After so many of these type notes wanted to give a different take.. The board..your comments insult some very established people. Fred Hassan and Kindler both ran major drug companies..my take is they are bullish on the health area and don’t want to see an IPO and give away a valuable part of the firm.. This is a completely disingenuous and dangerous take. Your suggestion that the likes of Hassan and Kindler (both comfortably wealthy and neither continual, nor considerable buyers of XON stock) are now bullish and protective of the potential of health care selectively ignores their 1000% failure to persuade RJK to protect shareholders over the past 4-5yrs. The others along with them have given guidance on cutting spending and focus on shareholder value.. Again, potentially too little too late. Where were they when Kirk was spouting off 4X a year about all the imminent "discussions, deals, and partnerships" that would prove out the success of the ECC business model? Where were they every time RJK told investors he was a few months away from reaching into massive addressable markets?? It is an undeniable fact that this BOD stood idly by as Kirk ran XON into the ground. Of course they now have to face the music and cut spending and focus on recovering whatever value they can hope to get! Duh! A BOD comprised of algorithms could do a better job than this crew. I just led a little group to do some due diligence and the firm is making progress on the established goals.. Who was your "little group" composed of? Rob Cos? Kchris? Redwood? Sounds far more like the "Three Blind Mice" to anyone who has ever conducted real and substantial due diligence! If they sell two units a box checked. Damn straight.....they friggin have to in order to survive and give health (their best asset) a chance to succeed. Selling off unrelated and unprofitable units, especially at bargain prices, is hardly any victory! Removal of he ongoing statement another box checked.. Keep checking those survival kit boxes. Helluva corporate strategy when your equity trades at 25% five years post it's IPO in a rampant bull market! How convenient to ignore this in a rose-colored lens incomplete analysis. Drug development..I would encourage the readers to start going to ASCO and ASH and see what drug development is all about.. How long it takes to get into the clinic and then take a look at what Hellen has done..same can be said for heart and the other programs.lots of shots on goal that should attract some partner interest.. Helen and Precigen may well succeed, but as you correctly note, it's years and we should note; hundreds of millions of dollars away. It is also quite binary and will require early indication positive results to find a suitable partner. Ever study game theory or play a game of chance? Expected outcomes come in all sizes and shapes. Energy..when the deal goes into effect we have a well connected person to take this to the next level..10 million is the number for the engineers to get the plans ready6-9 months..and then a year for the plant..the partner is well connected in Texas and if his scales up we have a winner.. This was a last ditch strategy once the Street's premier investment bank came up Snake Eyes for a program that was touted to pay off years ago in billions. Face it, Kirk couldn't find a big petrochemical partner willing to risk, what was for them, a mere pittance to bet on his overhyped and underpromised plant and product. I think the Lt. Governor took a measured shot catching Kirk's Hail Mary pass. Only (more) time and mo money will tell! Crop protection..I posted an abstract that showed progress this week and more coming ..this could be another area where they partner and get royalties .. Perhaps this could amount to a nice tidy little business, but it'll take real money, partners and testing to get to a commercial scale. Abstracts work only to protect academics, not plants, from maggots. The plans are laid out..sell a unit this quarter.. Have Hellen be a feature on the next call with updates..keep in mind nobody has ever done POC thought they don’t call it that and Nobody added MB-IL15..the second trial becomes more important than the first as it suggests safety is ok in the first trial. Then we have the PD1 and the therapeutic vaccine for two more trial Hellen will get going..from several sources Interest is high in these assets.. I agree this is the undeniable wager....although the odds are somewhere between Baccarat and Roulette. Sad thing is there is no bustier-wearing waitress to ease the pain with free drinks while the game is dealt. When you have health 90% of your phase ones fail.. With synthetic biology the potential to test the novel design elements long before a clinical trial and It is thought that we are seeing the benefits of this today with, e.g., PRGN 3005 and 3006. It took six years to get it right and into the clinic but as to the clinical performance it is not as if there is a lot there to wonder about in proof of concept..synthetic biology again is a first and This means data will be our catalyst and as trials are now underway data we will have.. Banque or Black, put your chips down. Better round up all the "markers" you can! Those of us that were in SCIO and CLDA saw a longer process than we thought at the time.. Short attacks..RJ called every name in the book..but guess what..he sold both and the shareholders were rewarded.. Different time and different place. All of SCIO and CLDA were established, derisked products...not ambitious and over promoted science experiments. I just wish those that attack would spend time at the conferences and annual meetings..look at the data.. Enough do to see that the data is premature and far, far from commercialized at present. If it was so compelling we'd have no reason to doubt management and the BOD, but alas at 5.77 a share, we have plenty of realistic reasons. Condemn them..he has bought heavy in the open market sending a message he believes still.. He has little choice but to make those purchases. No one save for Bill Miller averaging down has! Funny thing is that the BOD hasn't voted with their wallets and followed him in! Why is that? If the likes of Hassan, Kindler, et.al. are so bullish why aren't they buying hundreds of thousands of shares at these "presumed" cheap levels?? Do tell us why! That doesn’t guarantee success but it does give some light as to what the person in charge thinks of his team.. What other options exist for a uber-wealthy, narcissistic polymath wishing to try to convince his staff he still believes?? my due diligence gives me comfort to invest along side him! Real due diligence measures risk from every perspective. It isn't some simpleton first level, or even primary derivative analysis that wholesale buys into managerial promotion and hype. Granted, at this level there is far more reward than risk, yet the operational history of management, governance and the underlying science mandates healthy skepticism and demands inconvertible proof instead of promotional bullshit. Try focusing on the former instead of the latter and you'll learn a whole lot more. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
35024 | Re: Nice try at spin, Cptspr, but it comes up woefully shallow. | Redwood1205 | 3 | 8/24/2019 11:19:18 AM |
35030 | Re: Nice try at spin, -(Lack of BOD Buying Is seen as a Tell by Many) | Wall Street Teacher | 2 | 8/24/2019 9:05:26 PM |